ALBANY, N.Y., March 11, 2016 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) today announced that it has filed with the U.S. Securities
and Exchange Commission (SEC) a Form 12b-25 Notification of Late
Filing with regard to its Annual Report on Form 10-K for the year
ended December 31, 2015 to finalize
its consolidated financial statements due to greater complexity
connected with the Company's four acquisitions in 2015. The Company
expects such consolidated financial statements will be consistent
with the results of operations discussed in a press release issued
on February 17, 2016.
"We completed four significant acquisitions in 2015, following
two others in 2014," said William S.
Marth, AMRI's president and chief executive officer. "These
transformative additions have greatly expanded our capabilities and
revenue base, and have also added to the complexity of our
financial reporting. We have increased our internal financial and
accounting staffing and we are working to complete all remaining
matters and expect to file our Form 10-K no later than March 30, 2016."
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent and cytotoxic compounds, controlled substances, steroids,
peptides, hormones, and sterile API. DPM supports development
through commercial scale production of complex liquid-filled and
lyophilized parenterals, sterile suspensions and ophthalmic
formulations. For more information about AMRI, please visit our
website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
Forward-Looking Statements
This press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve risks
and uncertainties. These statements include, but are not
limited to, statements concerning the timing of the filing of the
Company's Annual Report on Form 10-K for the year ended
December 31, 2015 and statements
regarding the effects of the Company's business acquisitions.
Readers should not place undue reliance on our forward-looking
statements. The Company's actual results may differ
materially from such forward-looking statements as a result of
numerous factors, some of which the Company may not be able to
predict and may not be within the Company's control. Factors that
could cause such differences include, but are not limited to, the
ability of the Company to finalize its consolidated financial
statements and realize the expected financial contributions of the
acquired businesses, as well as those risks discussed in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2014 as filed with the
Securities and Exchange Commission on March
16, 2015, and the Company's other SEC filings. If the
Company's 2015 results of operations are not consistent with the
results of operations disclosed in the Company's earnings press
release issued on February 17, 2016,
the Company's stock price could decline.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-announces-extension-to-file-form-10k-for-2015-300234972.html
SOURCE AMRI